Abstract library

267 results for "17AAG".
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...
#2726 Clinicopathological Characterization of Gastroenteropancreatic Neuroendocrine Tumors in a Single Institute of North Africa: A Retrospective Study of 80 Cases
Introduction: The management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is based on a variety of factors including stage, anatomic location, and the presence and type of symptoms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira
#2760 Management and Outcomes of Duodenal Neuroendocrine Tumours
Introduction: Duodenal NENs (D-NENs) are increasing in incidence often incidentally identified at endoscopy. ENETS guidelines suggest endoscopic resection for duodenal NETs
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Alexandra Victor
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2806 Sarcopenia: Don't Judge a Book by It's Cover
Introduction: Sarcopenia is characterised by loss of muscle mass and function. We previously reported anthropometrical data for a range of NET diagnoses within 3 months of diagnosis. The majority of NET patients were overweight or obese, however reduced muscle function was observed in over half of patients regardless of BMI and other parameters.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Tara Whyand
#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Diego Carrillo
#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels
Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?
Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: PD Dr. Daniel Kaemmerer
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova